Neurocrine Biosciences (NBIX) News Today $109.75 +0.07 (+0.06%) Closing price 04:00 PM EasternExtended Trading$122.75 +13.00 (+11.85%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call TranscriptMay 5 at 9:31 PM | seekingalpha.comNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial GuidanceMay 5 at 4:01 PM | prnewswire.comNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive DyskinesiaMay 5 at 8:30 AM | prnewswire.comNorthern Trust Corp Has $134.04 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Northern Trust Corp boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 27.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 981,939 shares of the company's stock after purchasing aMay 5 at 5:02 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Stifel Financial CorpStifel Financial Corp grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,676 shares of the company's stock aftMay 5 at 4:13 AM | marketbeat.comNeurocrine Biosciences (NBIX) Prepares for Q1 Earnings AnnouncementMay 4 at 6:14 PM | gurufocus.comNeurocrine Biosciences (NBIX) Prepares for Q1 Earnings AnnouncementMay 4 at 6:14 PM | gurufocus.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Caisse DE Depot ET Placement DU QuebecCaisse DE Depot ET Placement DU Quebec grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 748,359May 4 at 5:37 AM | marketbeat.comDimensional Fund Advisors LP Acquires 26,525 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Dimensional Fund Advisors LP grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 550,157 shares of the company's stock afMay 3 at 4:02 AM | marketbeat.comNeurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on MondayMay 3 at 2:42 AM | americanbankingnews.comWhat to Expect from Neurocrine Biosciences's EarningsMay 2 at 7:46 PM | benzinga.comNeurocrine begins Phase III programme for schizophrenia treatmentMay 2 at 8:23 AM | msn.comNeurocrine Biosciences (NBIX) to Release Quarterly Earnings on WednesdayNeurocrine Biosciences (NASDAQ:NBIX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-neurocrine-biosciences-inc-stock/)May 2 at 7:11 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Soros Fund Management LLCSoros Fund Management LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 33.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 200,000 shares of the company'May 1, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by PDT Partners LLCPDT Partners LLC lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 133.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,748 shares of the company's stock after purchasing an additMay 1, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by AQR Capital Management LLCAQR Capital Management LLC grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,896,891 shares of the company's stock after acquMay 1, 2025 | marketbeat.comNxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with SchizophreniaApril 30, 2025 | globenewswire.comNeurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside PotentialApril 30, 2025 | insidermonkey.comNeurocrine Biosciences (NBIX) Launches Phase 3 Trial for Schizophrenia Treatment | NBIX Stock NewsApril 30, 2025 | gurufocus.comCanaccord Genuity Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $158.00Canaccord Genuity Group lowered their price target on Neurocrine Biosciences from $163.00 to $158.00 and set a "buy" rating on the stock in a report on Monday.April 30, 2025 | marketbeat.comNeurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with SchizophreniaApril 30, 2025 | prnewswire.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Voya Investment Management LLCVoya Investment Management LLC lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 139,441 shares of the company's stock after acquiring an additional 16,373 shareApril 30, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Acquires Shares of 114,661 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Susquehanna Fundamental Investments LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 114,661 shares of the compApril 29, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 184,663 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Price T Rowe Associates Inc. MD trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 11.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,490,513 shares of the company's stockApril 29, 2025 | marketbeat.comJump Financial LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Jump Financial LLC trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 95.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,676 shares of the company's stock afteApril 29, 2025 | marketbeat.comFY2025 EPS Estimates for NBIX Decreased by Cantor FitzgeraldApril 29, 2025 | americanbankingnews.comNBIX FY2025 EPS Forecast Reduced by Cantor FitzgeraldNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Neurocrine Biosciences in a note issued to investors on Friday, April 25th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earninApril 29, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock PriceApril 29, 2025 | americanbankingnews.comNeurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?April 29, 2025 | msn.comHsbc Holdings PLC Has $29 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Hsbc Holdings PLC reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 212,354 shares of the company's stApril 28, 2025 | marketbeat.comBrokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Target Price at $161.14April 28, 2025 | americanbankingnews.comSyon Capital LLC Purchases New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Syon Capital LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,666 shares of the company's stock, valApril 27, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Rating of "Moderate Buy" from AnalystsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-two ratings firms that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nineteen haveApril 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for NBIX Q1 Earnings?Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - HC Wainwright cut their Q1 2025 EPS estimates for shares of Neurocrine Biosciences in a report released on Tuesday, April 22nd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.25) for theApril 26, 2025 | marketbeat.comTower Research Capital LLC TRC Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tower Research Capital LLC TRC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 368.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,580 shares of the company's stock aftApril 26, 2025 | marketbeat.comEvercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)April 26, 2025 | markets.businessinsider.comResearch Analysts Issue Forecasts for NBIX FY2026 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report released on Tuesday, April 22nd. HC Wainwright analyst A. Fein now forecasts that the company wiApril 25, 2025 | marketbeat.comHood River Capital Management LLC Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Hood River Capital Management LLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 34.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 355,058 shares of the company's stock after acquiringApril 25, 2025 | marketbeat.comFirst Trust Advisors LP Sells 149,669 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)First Trust Advisors LP trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 27.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 394,652 shares of the company's stock afteApril 25, 2025 | marketbeat.comCanada Pension Plan Investment Board Sells 16,700 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Canada Pension Plan Investment Board lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 32.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,100 shares of the company's stocApril 25, 2025 | marketbeat.comMariner LLC Has $2.82 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Mariner LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 23.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,639 shares of the company's stock after purchasing anApril 25, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock PriceApril 25, 2025 | americanbankingnews.comNeurocrine announces publication of a post-hoc analysis of IngrezzaApril 25, 2025 | markets.businessinsider.comNeurocrine Biosciences publishes positive data from movement disorder studyApril 25, 2025 | msn.comNeurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical PsychiatryApril 24, 2025 | prnewswire.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $168.00 by Analysts at HC WainwrightHC Wainwright cut their price target on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a report on Tuesday.April 24, 2025 | marketbeat.comTeachers Retirement System of The State of Kentucky Boosts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Teachers Retirement System of The State of Kentucky raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 84.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,120 shaApril 24, 2025 | marketbeat.comMetLife Investment Management LLC Boosts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)MetLife Investment Management LLC lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,442 shares of theApril 24, 2025 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Has $1.68 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)BI Asset Management Fondsmaeglerselskab A S lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 28.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,322 shares of the company's stApril 24, 2025 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Neurocrine (NBIX)April 23, 2025 | markets.businessinsider.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.780.72▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼3215▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Incyte News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredU.S. Stock Market Now on Verge of CollapseThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
